GlaxoSmithKline submits revised disclosure

22 Mar 2017 Evaluate

The Exchange has now received the revised disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1) (a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for GlaxoSmithKline.

The above information is a part of company’s filings submitted to BSE.

Glaxosmithkline Phar Share Price

2311.50 -68.35 (-2.87%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×